NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

內容許可市場的全球電子臨床結果評估 (eCOA)的全球市場 - 產業趨勢與預測 (2028年)

Global eCOA for Content Licensed) Market- Industry Trends and Forecast to 2028

出版商 Data Bridge Market Research Private Limited 商品編碼 1014934
出版日期 內容資訊 英文 211 Pages
商品交期: 最快1-2個工作天內
價格
內容許可市場的全球電子臨床結果評估 (eCOA)的全球市場 - 產業趨勢與預測 (2028年) Global eCOA for Content Licensed) Market- Industry Trends and Forecast to 2028
出版日期: 2021年04月01日內容資訊: 英文 211 Pages
簡介

內容許可市場的全球電子臨床結果評估 (eCOA) 市場,2021年∼2028年的預測期間內將以14.4%的年複合成長率成長。

報告提供全球內容許可市場的全球電子臨床結果評估 (eCOA) 市場相關相關分析,市場概要,各市場區隔的市場分析,各地區的市場分析,主要企業等相關的系統性資訊。

目錄

第1章 簡介

第2章 市場區隔

第3章 摘要整理

第4章 重要考察

第5章 市場概要

  • 促進因素
  • 阻礙因素
  • 機會
  • 課題

第6章 內容許可市場的全球電子臨床結果評估 (eCOA) 市場:各產品

  • 概要
  • 內部部署解決方案
  • 雲端基礎解決方案
  • Web為基礎的解決方案

第7章 內容許可市場的全球電子臨床結果評估 (eCOA) 市場:各方法

  • 概要
  • 醫療者評估的結果(ClinRO)
  • 病人報告結果(PRO)
  • 看護者評估的結果(ObsRO)
  • 效能結果(PerfO)

第8章 內容許可市場的全球電子臨床結果評估 (eCOA) 市場:各終端用戶

  • 概要
  • 研究所、學術機構
  • 醫院、移植中心
  • 民間服務供應商

第9章 內容許可市場的全球電子臨床結果評估 (eCOA) 市場:各平台

  • 概要
  • 醫藥品臨床研究委外機構 (CRO)
  • 製藥企業、生物醫藥品企業
  • 醫療設備廠商
  • 醫院、臨床檢驗室
  • 諮詢服務企業
  • 研究、學術機構
  • 其他

第10章 內容許可市場的全球電子臨床結果評估 (eCOA) 市場:各地區

  • 概要
  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 西班牙
    • 法國
    • 義大利
    • 瑞士
    • 荷蘭
    • 比利時
    • 土耳其
    • 俄羅斯
    • 其他的歐洲
  • 亞太地區
    • 中國
    • 日本
    • 澳洲
    • 韓國
    • 印度
    • 新加坡
    • 泰國
    • 馬來西亞
    • 印尼
    • 菲律賓
    • 其他的亞太地區
  • 中東、非洲
    • 南非
    • 阿拉伯聯合大公國
    • 以色列
    • 沙烏地阿拉伯
    • 埃及
    • 其他中東、非洲
  • 南美
    • 巴西
    • 阿根廷
    • 其他南美

第11章 內容許可市場的全球電子臨床結果評估 (eCOA) 市場:企業形勢

  • 企業佔有率分析:世界
  • 企業佔有率分析:北美
  • 企業佔有率分析:歐洲
  • 企業佔有率分析:亞太地區

第12章 SWOT分析

第13章 企業簡介

  • ORACLE
  • PAREXEL INTERNATIONAL CORPORATION
  • ERT CLINICAL
  • DASSAULT SYSTEMES
  • BIOCLINICA
  • IBM CORPORATION
  • CLINICAL INK
  • KAYENTIS
  • ANJU SOFTWARE, INC.
  • ARISGLOBAL
  • ECLINICAL SOLUTIONS LLC
  • SIGNANT HEALTH
  • WIRB-COPERNICUS GROUP
  • YPRIME LLC

第14章 問卷調查

第15章 相關報告

目錄

Global electronic clinical outcome assessment (eCOA) for content licensed market is projected to register a CAGR of 14.4% in the forecast period of 2021 to 2028. The new market report contains data for historic year 2019, the base year of calculation is 2020 and the forecast period is 2021 to 2028

Market Segmentation

Global Electronic Clinical Outcome Assessment (eCOA) for Content Licensed Market, By Product (On-Premise Solutions, Cloud-Based Solutions, Web Based Solutions), Approach (Clinician Reported Outcome Assessment (ClinRO), Patient Reported Outcome Assessment (PRO), Observer Reported Outcome Assessment (ObsRO), Performance Outcome Assessment (PerfO)), End User (Commercial Service Providers, Hospitals and Transplant Centers, Research Laboratories, Academic Institutions), Platform (Contract Research Organizations, Pharmaceutical and Biopharmaceutical Companies, Medical Device Manufacturers, Hospitals and Clinical Laboratories, Consulting Service Companies, Research and Academia, Others), Country (U.S., Canada and Mexico, Germany, U.K., France, Switzerland, Italy, Spain, Netherlands, Russia, Belgium, Turkey, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, South Africa, UAE, Saudi Arabia, Israel, Egypt and Rest of Middle East & Africa, Brazil, Argentina, and Rest of South America) Industry Trends and Forecast to 2028

Some of the major factors contributing to the growth of the global electronic clinical outcome assessment (eCOA) for content licensed market:

The rise of electronic clinical outcome assessments (eCOAs) in the age of patient centricity

Growing demand for eCOA due to its capability to collect large amounts of data while simultaneously ensuring high quality

Market Players

Some of the major players operating in the global electronic clinical outcome assessment (eCOA) for content licensed market are:

Oracle

IBM Corporation

Dassault Systemes

Parexel International Corporation

ERT Clinical

eClinical Solutions LLC

ArisGlobal

Clinical Ink

Kayentis

Anju Software, Inc.

Signant Health

WIRB-Copernicus Group

YPrime LLC

Bioclinica

TABLE OF CONTENTS

1 INTRODUCTION 22

  • 1.1 OBJECTIVES OF THE STUDY 22
  • 1.2 MARKET DEFINITION 22
  • 1.3 OVERVIEW OF GLOBAL ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET 22
  • 1.4 LIMITATIONS 24
  • 1.5 MARKETS COVERED 24

2 MARKET SEGMENTATION 27

  • 2.1 MARKETS COVERED 27
  • 2.2 GEOGRAPHICAL SCOPE 28
  • 2.3 YEARS CONSIDERED FOR THE STUDY 29
  • 2.4 CURRENCY AND PRICING 29
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL 30
  • 2.6 MULTIVARIATE MODELLING 33
  • 2.7 GLOBAL PRODUCT LIFELINE CURVE 34
  • 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 34
  • 2.9 DBMR MARKET POSITION GRID 35
  • 2.10 VENDOR SHARE ANALYSIS 37
  • 2.11 SECONDARY SOURCES 38
  • 2.12 ASSUMPTIONS 38

3 EXECUTIVE SUMMARY 39

4 PREMIUM INSIGHTS 41

5 MARKET OVERVIEW 44

  • 5.1 DRIVERS 46
    • 5.1.1 RISE OF ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) IN THE AGE OF PATIENT CENTRICITY 46
    • 5.1.2 GROWING DEMAND FOR ECOA DUE TO ITS CAPABILITY TO COLLECT LARGE AMOUNTS OF DATA WHILE SIMULTANEOUSLY ENSURING HIGH QUALITY 47
    • 5.1.3 EMERGING TECHNOLOGICAL TRENDS BY PROVIDING A GREATER UNDERSTANDING OF EDC AND ECOA/EPRO PENETRATION IN PHARMACEUTICAL MARKETS 47
    • 5.1.4 GROWING ACCEPTANCE OF ECOA TO ENGAGE MORE CLOSELY WITH PATIENTS BY PHARMA INDUSTRY 48
    • 5.1.5 RISING NEED TOWARDS ELECTRONIC DATA CAPTURING FOR EFFICIENCY OF CLINICAL TRIALS 48
    • 5.1.6 COST-EFFICIENCY AND RELIABILITY PROVIDED BY THE ECOA 49
    • 5.1.7 RISING NUMBER OF CLINICAL TRIALS REGULATED BY FDA AND APPROVED BY INSTITUTIONAL REVIEW BOARD (IRB) FOR PATIENT SAFETY IN MULTI-CENTER TRIALS 50
  • 5.2 RESTRAINTS 51
    • 5.2.1 HIGH INITIAL COSTS ASSOCIATED WITH THE IMPLEMENTATION AND UTILIZATION OF THE SYSTEMS 51
    • 5.2.2 LACK OF AWARENESS ABOUT REGULATIONS RELATED TO THE DATA MANAGEMENT 51
  • 5.3 OPPORTUNITIES 52
    • 5.3.1 RISING LEVELS OF INNOVATIONS AND ADVANCED TECHNOLOGIES 52
    • 5.3.2 INCREASING PARTNERSHIPS AND COLLABORATIONS FOR CLINICAL RESEARCHES 53
    • 5.3.3 DIGITIZATION OF CLINICAL TRIALS AIMS AT PERFORMING THEIR END-TO-END DIGITAL TRANSFORMATION 54
    • 5.3.4 INCREASING COLLABORATION BETWEEN INDUSTRY AND GOVERNMENT FOR CLINICAL TRIALS UNDER GOVERNMENT POLICIES 54
  • 5.4 CHALLENGES 55
    • 5.4.1 LACK OF WELL-TRAINED PROFESSIONALS FOR ACCURATE DATA INTERPRETATION 55
    • 5.4.2 LACK OF PROPER IT INFRASTRUCTURE IN MANY DEVELOPING COUNTRIES 56

6 GLOBAL ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT 57

  • 6.1 OVERVIEW 58
  • 6.2 ON-PREMISE SOLUTIONS 59
  • 6.3 CLOUD BASED SOLUTIONS 60
  • 6.4 WEB BASED SOLUTIONS 60

7 GLOBAL ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH 62

  • 7.1 OVERVIEW 63
  • 7.2 CLINICIAN REPORTED OUTCOME ASSESSMENT (CLINRO) 64
  • 7.3 PATIENT REPORTED OUTCOME ASSESSMENT (PRO) 65
  • 7.4 OBSERVER REPORTED OUTCOME ASSESSMENT (OBSRO) 65
  • 7.5 PERFORMANCE OUTCOME ASSESSMENT (PERFO) 66

8 GLOBAL ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER 67

  • 8.1 OVERVIEW 68
  • 8.2 RESEARCH LABORATORIES AND ACADEMIC INSTITUTIONS 69
  • 8.3 HOSPITALS AND TRANSPLANT CENTERS 70
  • 8.4 COMMERCIAL SERVICE PROVIDERS 70

9 GLOBAL ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM 72

  • 9.1 OVERVIEW 73
  • 9.2 CONTRACT RESEARCH ORGANIZATIONS 74
  • 9.3 PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES 75
  • 9.4 MEDICAL DEVICE MANUFACTURERS 75
  • 9.5 HOSPITALS AND CLINICAL LABORATORIES 76
  • 9.6 CONSULTING SERVICE COMPANIES 76
  • 9.7 RESEARCH AND ACADEMIA 77
  • 9.8 OTHERS 78

10 GLOBAL ELECTRONIC CLINICAL OUTCOME ASSESSMENT FOR CONTENT LICENSED MARKET, BY REGION 79

  • 10.1 OVERVIEW 80
  • 10.2 NORTH AMERICA 85
    • 10.2.1 U.S. 90
    • 10.2.2 CANADA 92
    • 10.2.3 MEXICO 94
  • 10.3 EUROPE 96
    • 10.3.1 U.K. 101
    • 10.3.2 GERMANY 103
    • 10.3.3 SPAIN 105
    • 10.3.4 FRANCE 107
    • 10.3.5 ITALY 109
    • 10.3.6 SWITZERLAND 111
    • 10.3.7 NETHERLANDS 113
    • 10.3.8 BELGIUM 115
    • 10.3.9 TURKEY 117
    • 10.3.10 RUSSIA 119
    • 10.3.11 REST OF EUROPE 121
  • 10.4 ASIA-PACIFIC 122
    • 10.4.1 CHINA 127
    • 10.4.2 JAPAN 129
    • 10.4.3 AUSTRALIA 131
    • 10.4.4 SOUTH KOREA 133
    • 10.4.5 INDIA 135
    • 10.4.6 SINGAPORE 137
    • 10.4.7 THAILAND 139
    • 10.4.8 MALAYSIA 141
    • 10.4.9 INDONESIA 143
    • 10.4.10 PHILIPPINES 145
    • 10.4.11 REST OF ASIA-PACIFIC 147
  • 10.5 MIDDLE EAST AND AFRICA 148
    • 10.5.1 SOUTH AFRICA 153
    • 10.5.2 UAE 155
    • 10.5.3 ISRAEL 157
    • 10.5.4 SAUDI ARABIA 159
    • 10.5.5 EGYPT 161
    • 10.5.6 REST OF MIDDLE EAST AND AFRICA 163
  • 10.6 SOUTH AMERICA 164
    • 10.6.1 BRAZIL 169
    • 10.6.2 ARGENTINA 171
    • 10.6.3 REST OF SOUTH AMERICA 173

11 GLOBAL ELECTRONIC CLINICAL OUTCOME ASSESSMENT FOR CONTENT LICENSED MARKET: COMPANY LANDSCAP 174

  • 11.1 COMPANY SHARE ANALYSIS: GLOBAL 174
  • 11.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 175
  • 11.3 COMPANY SHARE ANALYSIS: EUROPE 176
  • 11.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 177

12 SWOT ANALYSIS 178

13 COMPANY PROFILE 179

  • 13.1 ORACLE 179
    • 13.1.1 COMPANY SNAPSHOT 179
    • 13.1.2 REVENUE ANALYSIS 179
    • 13.1.3 COMPANY SHARE ANALYSIS 180
    • 13.1.4 PRODUCT PORTFOLIO 180
    • 13.1.5 RECENT DEVELOPMENTS 180
  • 13.2 PAREXEL INTERNATIONAL CORPORATION 182
    • 13.2.1 COMPANY SNAPSHOT 182
    • 13.2.2 COMPANY SHARE ANALYSIS 182
    • 13.2.3 PRODUCT PORTFOLIO 182
    • 13.2.4 RECENT DEVELOPMENTS 183
  • 13.3 ERT CLINICAL 184
    • 13.3.1 COMPANY SNAPSHOT 184
    • 13.3.2 COMPANY SHARE ANALYSIS 184
    • 13.3.3 PRODUCT PORTFOLIO 184
    • 13.3.4 RECENT DEVELOPMENTS 185
  • 13.4 DASSAULT SYSTEMES 186
    • 13.4.1 COMPANY SNAPSHOT 186
    • 13.4.2 REVENUE ANALYSIS 186
    • 13.4.3 COMPANY SHARE ANALYSIS 187
    • 13.4.4 PRODUCT PORTFOLIO 187
    • 13.4.5 RECENT DEVELOPMENTS 187
  • 13.5 BIOCLINICA 189
    • 13.5.1 COMPANY SNAPSHOT 189
    • 13.5.2 COMPANY SHARE ANALYSIS 189
    • 13.5.3 PRODUCT PORTFOLIO 189
    • 13.5.4 RECENT DEVELOPMENTS 190
  • 13.6 IBM CORPORATION 191
    • 13.6.1 COMPANY SNAPSHOT 191
    • 13.6.2 REVENUE ANALYSIS 191
    • 13.6.3 PRODUCT PORTFOLIO 192
    • 13.6.4 RECENT DEVELOPMENTS 192
  • 13.7 CLINICAL INK 193
    • 13.7.1 COMPANY SNAPSHOT 193
    • 13.7.2 PRODUCT PORTFOLIO 193
    • 13.7.3 RECENT DEVELOPMENTS 193
  • 13.8 KAYENTIS 194
    • 13.8.1 COMPANY SNAPSHOT 194
    • 13.8.2 PRODUCT PORTFOLIO 194
    • 13.8.3 RECENT DEVELOPMENTS 194
  • 13.9 ANJU SOFTWARE, INC. 195
    • 13.9.1 COMPANY SNAPSHOT 195
    • 13.9.2 PRODUCT PORTFOLIO 195
    • 13.9.3 RECENT DEVELOPMENTS 195
  • 13.10 ARISGLOBAL 197
    • 13.10.1 COMPANY SNAPSHOT 197
    • 13.10.2 PRODUCT PORTFOLIO 197
    • 13.10.3 RECENT DEVELOPMENTS 197
  • 13.11 ECLINICAL SOLUTIONS LLC 198
    • 13.11.1 COMPANY SNAPSHOT 198
    • 13.11.2 PRODUCT PORTFOLIO 198
    • 13.11.3 RECENT DEVELOPMENTS 198
  • 13.12 SIGNANT HEALTH 200
    • 13.12.1 COMPANY SNAPSHOT 200
    • 13.12.2 SOLUTION PORTFOLIO 200
    • 13.12.3 RECENT DEVELOPMENTS 200
  • 13.13 WIRB-COPERNICUS GROUP 202
    • 13.13.1 COMPANY SNAPSHOT 202
    • 13.13.2 SERVICE PORTFOLIO 202
    • 13.13.3 RECENT DEVELOPMENTS 202
  • 13.14 YPRIME LLC 204
    • 13.14.1 COMPANY SNAPSHOT 204
    • 13.14.2 PRODUCT PORTFOLIO 204
    • 13.14.3 RECENT DEVELOPMENTS 204

14 QUESTIONNAIRE 206

15 RELATED REPORTS 211

LIST OF TABLES

  • TABLE 1 GLOBAL ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND) 59
  • TABLE 2 GLOBAL ON-PREMISE SOLUTIONS IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND) 59
  • TABLE 3 GLOBAL CLOUD BASED SOLUTIONS IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND) 60
  • TABLE 4 GLOBAL WEB BASED SOLUTIONS IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND) 61
  • TABLE 5 GLOBAL ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH, 2019-2028 (USD THOUSAND) 64
  • TABLE 6 GLOBAL CLINICIAN REPORTED OUTCOME ASSESSMENT (CLINRO) IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND) 64
  • TABLE 7 GLOBAL PATIENT REPORTED OUTCOME ASSESSMENT (PRO) IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND) 65
  • TABLE 8 GLOBAL OBSERVER REPORTED OUTCOME ASSESSMENT (OBSRO) IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND) 66
  • TABLE 9 GLOBAL PERFORMANCE OUTCOME ASSESSMENT (PERFO) IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND) 66
  • TABLE 10 GLOBAL ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER, 2019-2028 (USD THOUSAND) 69
  • TABLE 11 GLOBAL RESEARCH LABORATORIES AND ACADEMIC INSTITUTIONS IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND) 69
  • TABLE 12 GLOBAL HOSPITALS AND TRANSPLANT CENTERS IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND) 70
  • TABLE 13 GLOBAL COMMERCIAL SERVICE PROVIDERS IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND) 71
  • TABLE 14 GLOBAL ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM, 2019-2028 (USD THOUSAND) 74
  • TABLE 15 GLOBAL CONTRACT RESEARCH ORGANIZATIONS IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND) 74
  • TABLE 16 GLOBAL PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND) 75
  • TABLE 17 GLOBAL MEDICAL DEVICE MANUFACTURERS IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND) 76
  • TABLE 18 GLOBAL HOSPITALS AND CLINICAL LABORATORIES IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND) 76
  • TABLE 19 GLOBAL CONSULTING SERVICE COMPANIES IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND) 77
  • TABLE 20 GLOBAL RESEARCH AND ACADEMIA IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND) 78
  • TABLE 21 GLOBAL OTHERS IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND) 78
  • TABLE 22 GLOBAL ELECTRONIC OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND) 84
  • TABLE 23 NORTH AMERICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY COUNTRY, 2019-2028 (USD THOUSAND) 88
  • TABLE 24 NORTH AMERICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND) 88
  • TABLE 25 NORTH AMERICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH, 2019-2028 (USD THOUSAND) 88
  • TABLE 26 NORTH AMERICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER, 2019-2028 (USD THOUSAND) 89
  • TABLE 27 NORTH AMERICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM, 2019-2028 (USD THOUSAND) 89
  • TABLE 28 U.S. ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND) 90
  • TABLE 29 U.S. ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH, 2019-2028 (USD THOUSAND) 90
  • TABLE 30 U.S. ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER, 2019-2028 (USD THOUSAND) 90
  • TABLE 31 U.S. ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM, 2019-2028 (USD THOUSAND) 91
  • TABLE 32 CANADA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND) 92
  • TABLE 33 CANADA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH, 2019-2028 (USD THOUSAND) 92
  • TABLE 34 CANADA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER, 2019-2028 (USD THOUSAND) 92
  • TABLE 35 CANADA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM, 2019-2028 (USD THOUSAND) 93
  • TABLE 36 MEXICO ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND) 94
  • TABLE 37 MEXICO ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH, 2019-2028 (USD THOUSAND) 94
  • TABLE 38 MEXICO ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER, 2019-2028 (USD THOUSAND) 94
  • TABLE 39 MEXICO ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM, 2019-2028 (USD THOUSAND) 95
  • TABLE 40 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY COUNTRY, 2019-2028 (USD THOUSAND) 99
  • TABLE 41 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND) 99
  • TABLE 42 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH, 2019-2028 (USD THOUSAND) 100
  • TABLE 43 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER, 2019-2028 (USD THOUSAND) 100
  • TABLE 44 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM, 2019-2028 (USD THOUSAND) 100
  • TABLE 45 U.K. ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND) 101
  • TABLE 46 U.K. ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH, 2019-2028 (USD THOUSAND) 101
  • TABLE 47 U.K. ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER, 2019-2028 (USD THOUSAND) 101
  • TABLE 48 U.K. ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM, 2019-2028 (USD THOUSAND) 102
  • TABLE 49 GERMANY ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND) 103
  • TABLE 50 GERMANY ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH, 2019-2028 (USD THOUSAND) 103
  • TABLE 51 GERMANY ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER, 2019-2028 (USD THOUSAND) 103
  • TABLE 52 GERMANY ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM, 2019-2028 (USD THOUSAND) 104
  • TABLE 53 SPAIN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND) 105
  • TABLE 54 SPAIN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH, 2019-2028 (USD THOUSAND) 105
  • TABLE 55 SPAIN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER, 2019-2028 (USD THOUSAND) 105
  • TABLE 56 SPAIN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM, 2019-2028 (USD THOUSAND) 106
  • TABLE 57 FRANCE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND) 107
  • TABLE 58 FRANCE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH, 2019-2028 (USD THOUSAND) 107
  • TABLE 59 FRANCE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER, 2019-2028 (USD THOUSAND) 107
  • TABLE 60 FRANCE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM, 2019-2028 (USD THOUSAND) 108
  • TABLE 61 ITALY ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND) 109
  • TABLE 62 ITALY ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH, 2019-2028 (USD THOUSAND) 109
  • TABLE 63 ITALY ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER, 2019-2028 (USD THOUSAND) 109
  • TABLE 64 ITALY ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM, 2019-2028 (USD THOUSAND) 110
  • TABLE 65 SWITZERLAND ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND) 111
  • TABLE 66 SWITZERLAND ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH, 2019-2028 (USD THOUSAND) 111
  • TABLE 67 SWITZERLAND ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER, 2019-2028 (USD THOUSAND) 111
  • TABLE 68 SWITZERLAND ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM, 2019-2028 (USD THOUSAND) 112
  • TABLE 69 NETHERLANDS ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND) 113
  • TABLE 70 NETHERLANDS ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH, 2019-2028 (USD THOUSAND) 113
  • TABLE 71 NETHERLANDS ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER, 2019-2028 (USD THOUSAND) 113
  • TABLE 72 NETHERLANDS ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM, 2019-2028 (USD THOUSAND) 114
  • TABLE 73 BELGIUM ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND) 115
  • TABLE 74 BELGIUM ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH, 2019-2028 (USD THOUSAND) 115
  • TABLE 75 BELGIUM ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER, 2019-2028 (USD THOUSAND) 115
  • TABLE 76 BELGIUM ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM, 2019-2028 (USD THOUSAND) 116
  • TABLE 77 TURKEY ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND) 117
  • TABLE 78 TURKEY ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH, 2019-2028 (USD THOUSAND) 117
  • TABLE 79 TURKEY ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER, 2019-2028 (USD THOUSAND) 117
  • TABLE 80 TURKEY ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM, 2019-2028 (USD THOUSAND) 118
  • TABLE 81 RUSSIA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND) 119
  • TABLE 82 RUSSIA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH, 2019-2028 (USD THOUSAND) 119
  • TABLE 83 RUSSIA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER, 2019-2028 (USD THOUSAND) 119
  • TABLE 84 RUSSIA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM, 2019-2028 (USD THOUSAND) 120
  • TABLE 85 REST OF EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND) 121
  • TABLE 86 ASIA-PACIFIC ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY COUNTRY, 2019-2028 (USD THOUSAND) 125
  • TABLE 87 ASIA-PACIFIC ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND) 125
  • TABLE 88 ASIA-PACIFIC ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH, 2019-2028 (USD THOUSAND) 125
  • TABLE 89 ASIA-PACIFIC ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER, 2019-2028 (USD THOUSAND) 126
  • TABLE 90 ASIA-PACIFIC ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM, 2019-2028 (USD THOUSAND) 126
  • TABLE 91 CHINA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND) 127
  • TABLE 92 CHINA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH, 2019-2028 (USD THOUSAND) 127
  • TABLE 93 CHINA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER, 2019-2028 (USD THOUSAND) 127
  • TABLE 94 CHINA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM, 2019-2028 (USD THOUSAND) 128
  • TABLE 95 JAPAN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND) 129
  • TABLE 96 JAPAN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH, 2019-2028 (USD THOUSAND) 129
  • TABLE 97 JAPAN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER, 2019-2028 (USD THOUSAND) 129
  • TABLE 98 JAPAN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM, 2019-2028 (USD THOUSAND) 130
  • TABLE 99 AUSTRALIA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND) 131
  • TABLE 100 AUSTRALIA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH, 2019-2028 (USD THOUSAND) 131
  • TABLE 101 AUSTRALIA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER, 2019-2028 (USD THOUSAND) 131
  • TABLE 102 AUSTRALIA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM, 2019-2028 (USD THOUSAND) 132
  • TABLE 103 SOUTH KOREA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND) 133
  • TABLE 104 SOUTH KOREA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH, 2019-2028 (USD THOUSAND) 133
  • TABLE 105 SOUTH KOREA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER, 2019-2028 (USD THOUSAND) 133
  • TABLE 106 SOUTH KOREA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM, 2019-2028 (USD THOUSAND) 134
  • TABLE 107 INDIA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND) 135
  • TABLE 108 INDIA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH, 2019-2028 (USD THOUSAND) 135
  • TABLE 109 INDIA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER, 2019-2028 (USD THOUSAND) 135
  • TABLE 110 INDIA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM, 2019-2028 (USD THOUSAND) 136
  • TABLE 111 SINGAPORE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND) 137
  • TABLE 112 SINGAPORE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH, 2019-2028 (USD THOUSAND) 137
  • TABLE 113 SINGAPORE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER, 2019-2028 (USD THOUSAND) 137
  • TABLE 114 SINGAPORE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM, 2019-2028 (USD THOUSAND) 138
  • TABLE 115 THAILAND ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND) 139
  • TABLE 116 THAILAND ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH, 2019-2028 (USD THOUSAND) 139
  • TABLE 117 THAILAND ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER, 2019-2028 (USD THOUSAND) 139
  • TABLE 118 THAILAND ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM, 2019-2028 (USD THOUSAND) 140
  • TABLE 119 MALAYSIA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND) 141
  • TABLE 120 MALAYSIA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH, 2019-2028 (USD THOUSAND) 141
  • TABLE 121 MALAYSIA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER, 2019-2028 (USD THOUSAND) 141
  • TABLE 122 MALAYSIA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM, 2019-2028 (USD THOUSAND) 142
  • TABLE 123 INDONESIA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND) 143
  • TABLE 124 INDONESIA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH, 2019-2028 (USD THOUSAND) 143
  • TABLE 125 INDONESIA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER, 2019-2028 (USD THOUSAND) 143
  • TABLE 126 INDONESIA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM, 2019-2028 (USD THOUSAND) 144
  • TABLE 127 PHILIPPINES ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND) 145
  • TABLE 128 PHILIPPINES ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH, 2019-2028 (USD THOUSAND) 145
  • TABLE 129 PHILIPPINES ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER, 2019-2028 (USD THOUSAND) 145
  • TABLE 130 PHILIPPINES ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM, 2019-2028 (USD THOUSAND) 146
  • TABLE 131 REST OF ASIA-PACIFIC ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND) 147
  • TABLE 132 MIDDLE EAST AND AFRICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY COUNTRY, 2019-2028 (USD THOUSAND) 151
  • TABLE 133 MIDDLE EAST AND AFRICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND) 151
  • TABLE 134 MIDDLE EAST AND AFRICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH, 2019-2028 (USD THOUSAND) 151
  • TABLE 135 MIDDLE EAST AND AFRICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER, 2019-2028 (USD THOUSAND) 152
  • TABLE 136 MIDDLE EAST AND AFRICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM, 2019-2028 (USD THOUSAND) 152
  • TABLE 137 SOUTH AFRICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND) 153
  • TABLE 138 SOUTH AFRICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH, 2019-2028 (USD THOUSAND) 153
  • TABLE 139 SOUTH AFRICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER, 2019-2028 (USD THOUSAND) 153
  • TABLE 140 SOUTH AFRICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM, 2019-2028 (USD THOUSAND) 154
  • TABLE 141 UAE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND) 155
  • TABLE 142 UAE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH, 2019-2028 (USD THOUSAND) 155
  • TABLE 143 UAE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER, 2019-2028 (USD THOUSAND) 155
  • TABLE 144 UAE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM, 2019-2028 (USD THOUSAND) 156
  • TABLE 145 ISRAEL ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND) 157
  • TABLE 146 ISRAEL ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH, 2019-2028 (USD THOUSAND) 157
  • TABLE 147 ISRAEL ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER, 2019-2028 (USD THOUSAND) 157
  • TABLE 148 ISRAEL ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM, 2019-2028 (USD THOUSAND) 158
  • TABLE 149 SAUDI ARABIA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND) 159
  • TABLE 150 SAUDI ARABIA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH, 2019-2028 (USD THOUSAND) 159
  • TABLE 151 SAUDI ARABIA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER, 2019-2028 (USD THOUSAND) 159
  • TABLE 152 SAUDI ARABIA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM, 2019-2028 (USD THOUSAND) 160
  • TABLE 153 EGYPT ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND) 161
  • TABLE 154 EGYPT ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH, 2019-2028 (USD THOUSAND) 161
  • TABLE 155 EGYPT ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER, 2019-2028 (USD THOUSAND) 161
  • TABLE 156 EGYPT ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM, 2019-2028 (USD THOUSAND) 162
  • TABLE 157 REST OF MIDDLE EAST AND AFRICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND) 163
  • TABLE 158 SOUTH AMERICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY COUNTRY, 2019-2028 (USD THOUSAND) 167
  • TABLE 159 SOUTH AMERICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND) 167
  • TABLE 160 SOUTH AMERICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH, 2019-2028 (USD THOUSAND) 167
  • TABLE 161 SOUTH AMERICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER, 2019-2028 (USD THOUSAND) 167
  • TABLE 162 SOUTH AMERICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM, 2019-2028 (USD THOUSAND) 168
  • TABLE 163 BRAZIL ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND) 169
  • TABLE 164 BRAZIL ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH, 2019-2028 (USD THOUSAND) 169
  • TABLE 165 BRAZIL ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER, 2019-2028 (USD THOUSAND) 169
  • TABLE 166 BRAZIL ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM, 2019-2028 (USD THOUSAND) 170
  • TABLE 167 ARGENTINA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND) 171
  • TABLE 168 ARGENTINA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH, 2019-2028 (USD THOUSAND) 171
  • TABLE 169 ARGENTINA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER, 2019-2028 (USD THOUSAND) 171
  • TABLE 170 ARGENTINA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM, 2019-2028 (USD THOUSAND) 172
  • TABLE 171 REST OF SOUTH AMERICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND) 173

LIST OF FIGURES

  • FIGURE 1 GLOBAL ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: SEGMENTATION 27
  • FIGURE 2 GLOBAL ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: DATA TRIANGULATION 30
  • FIGURE 3 GLOBAL ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: DROC ANALYSIS 31
  • FIGURE 4 GLOBAL ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS 32
  • FIGURE 5 GLOBAL ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: COMPANY RESEARCH ANALYSIS 32
  • FIGURE 6 GLOBAL ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: INTERVIEW DEMOGRAPHICS 34
  • FIGURE 8 GLOBAL ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: VENDOR SHARE ANALYSIS 37
  • FIGURE 9 GLOBAL ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: SEGMENTATION 40
  • FIGURE 10 GROWING ACCEPTANCE OF ECOA TO ENGAGE MORE CLOSELY WITH PATIENTS BY PHARMA INDUSTRY IS EXPECTED TO DRIVE GLOBAL ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET IN THE FORECAST PERIOD OF 2021 TO 2028 41
  • FIGURE 11 ON-PREMISE SOLUTIONS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF GLOBAL ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET IN 2021 & 2028 41
  • FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE AND ASIA-PACIFIC IS THE FASTEST GROWING REGION IN GLOBAL ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET IN THE FORECAST PERIOD OF 2021 TO 2028 42
  • FIGURE 13 ASIA-PACIFIC IS THE FASTEST GROWING MARKET FOR ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MANUFACTURERS IN THE FORECAST PERIOD OF 2021 TO 2028 43
  • FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF GLOBAL ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET 45
  • FIGURE 15 GLOBAL ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: BY PRODUCT, 2020 58
  • FIGURE 16 GLOBAL ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: BY APPROACH, 2020 63
  • FIGURE 17 GLOBAL ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: BY END USER, 2020 68
  • FIGURE 18 GLOBAL ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: BY PLATFORM, 2020 73
  • FIGURE 19 GLOBAL ELECTRONIC OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: SNAPSHOT (2020) 81
  • FIGURE 20 GLOBAL ELECTRONIC OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: BY GEOGRAPHY (2020) 82
  • FIGURE 21 GLOBAL ELECTRONIC OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: BY GEOGRAPHY (2021 & 2028) 82
  • FIGURE 22 GLOBAL ELECTRONIC OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: BY GEOGRAPHY (2020 & 2028) 83
  • FIGURE 23 GLOBAL ELECTRONIC OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: BY PRODUCT (2021-2028) 83
  • FIGURE 24 NORTH AMERICA ELECTRONIC OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: SNAPSHOT (2020) 85
  • FIGURE 25 NORTH AMERICA ELECTRONIC OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: BY GEOGRAPHY (2020) 86
  • FIGURE 26 NORTH AMERICA ELECTRONIC OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: BY GEOGRAPHY (2021 & 2028) 86
  • FIGURE 27 NORTH AMERICA ELECTRONIC OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: BY GEOGRAPHY (2020 & 2028) 87
  • FIGURE 28 NORTH AMERICA ELECTRONIC OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: BY PRODUCT (2021-2028) 87
  • FIGURE 29 EUROPE ELECTRONIC OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: SNAPSHOT (2020) 96
  • FIGURE 30 EUROPE ELECTRONIC OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: BY GEOGRAPHY (2020) 97
  • FIGURE 31 EUROPE ELECTRONIC OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: BY GEOGRAPHY (2021 & 2028) 97
  • FIGURE 32 EUROPE ELECTRONIC OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: BY GEOGRAPHY (2020 & 2028) 98
  • FIGURE 33 EUROPE ELECTRONIC OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: BY PRODUCT (2021-2028) 98
  • FIGURE 34 ASIA-PACIFIC ELECTRONIC OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: SNAPSHOT (2020) 122
  • FIGURE 35 ASIA-PACIFIC ELECTRONIC OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: BY GEOGRAPHY (2020) 123
  • FIGURE 36 ASIA-PACIFIC ELECTRONIC OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: BY GEOGRAPHY (2021 & 2028) 123
  • FIGURE 37 ASIA-PACIFIC ELECTRONIC OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: BY GEOGRAPHY (2020 & 2028) 124
  • FIGURE 38 ASIA-PACIFIC ELECTRONIC OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: BY PRODUCT (2021-2028) 124
  • FIGURE 39 MIDDLE EAST AND AFRICA ELECTRONIC OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: SNAPSHOT (2020) 148
  • FIGURE 40 MIDDLE EAST AND AFRICA ELECTRONIC OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: BY GEOGRAPHY (2020) 149
  • FIGURE 41 MIDDLE EAST AND AFRICA ELECTRONIC OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: BY GEOGRAPHY (2021 & 2028) 149
  • FIGURE 42 MIDDLE EAST AND AFRICA ELECTRONIC OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: BY GEOGRAPHY (2020 & 2028) 150
  • FIGURE 43 MIDDLE EAST AND AFRICA ELECTRONIC OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: BY PRODUCT (2021-2028) 150
  • FIGURE 44 SOUTH AMERICA ELECTRONIC OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: SNAPSHOT (2020) 164
  • FIGURE 45 SOUTH AMERICA ELECTRONIC OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: BY GEOGRAPHY (2020) 165
  • FIGURE 46 SOUTH AMERICA ELECTRONIC OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: BY GEOGRAPHY (2021 & 2028) 165
  • FIGURE 47 SOUTH AMERICA ELECTRONIC OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: BY GEOGRAPHY (2020 & 2028) 166
  • FIGURE 48 SOUTH AMERICA ELECTRONIC OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: BY PRODUCT (2021-2028) 166
  • FIGURE 49 GLOBAL ELECTRONIC CLINICAL OUTCOME ASSESSMENT FOR CONTENT LICENSED MARKET: COMPANY SHARE 2020(%) 174
  • FIGURE 50 NORTH AMERICA ELECTRONIC OUTCOME ASSESSMENT FOR CONTENT LICENSED MARKET: COMPANY SHARE 2020(%) 175
  • FIGURE 51 EUROPE ELECTRONIC OUTCOME ASSESSMENT FOR CONTENT LICENSED MARKET: COMPANY SHARE 2020(%) 176
  • FIGURE 52 ASIA-PACIFIC ELECTRONIC OUTCOME ASSESSMENT FOR CONTENT LICENSED MARKET: COMPANY SHARE 2020(%) 177